Comparative effectiveness and safety of inclisiran versus evolocumab and alirocumab: a 180-day real-world study
BMC Cardiovascular Disorders · 2026-05-16 · 26 (1)
DOI: 10.1186/s12872-026-05931-5 ↗At a glance
Vergleichsstudie in BMC Cardiovascular Disorders, published online on 2026-05-16. Written by Jiafang Yao and 4 co-authors. Institution: Department of Cardiovascular Center, First affiliated Hospital of Huzhou University, No. 158 Plaza Back Road, Huzhou City, Zhejiang Province, 313000,…. Major MEDLINE topics: Antibodies, Monoclonal, Humanized, Cholesterol, LDL, PCSK9 Inhibitors, Anticholesteremic Agents. 45 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Funded by Huzhou Science and Technology Bureau, Public Welfare Applied Research Project.
Abstract (original language)
Intet abstract tilgængeligt.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Cardiovascular Center, First affiliated Hospital of Huzhou University, No. 158 Plaza Back Road, Huzhou City, Zhejiang Province, 313000, China.
- Department of Nephrology, Huzhou Central, Hospital, Huzhou, China.
- Department of Cardiovascular Center, First affiliated Hospital of Huzhou University, No. 158 Plaza Back Road, Huzhou City, Zhejiang Province, 313000, China. wwjyy0712@126.com.
Funding
- Funded by Huzhou Science and Technology Bureau, Public Welfare Applied Research Project
Cite
APA
Yao, J., Sun, Q., Liu, D., Lin, J., & Wang, W. (2026). Comparative effectiveness and safety of inclisiran versus evolocumab and alirocumab: a 180-day real-world study. BMC Cardiovascular Disorders, 26(1). https://doi.org/10.1186/s12872-026-05931-5
Vancouver
Yao J, Sun Q, Liu D, Lin J, Wang W. Comparative effectiveness and safety of inclisiran versus evolocumab and alirocumab: a 180-day real-world study. BMC Cardiovascular Disorders. 2026;26(1). doi:10.1186/s12872-026-05931-5
BibTeX
@article{Yao2026,
author = {Yao, Jiafang and Sun, Qiyin and Liu, Dan and Lin, Junling and Wang, WenJuan},
title = {Comparative effectiveness and safety of inclisiran versus evolocumab and alirocumab: a 180-day real-world study},
journal = {BMC Cardiovascular Disorders},
year = {2026},
volume = {26},
number = {1},
doi = {10.1186/s12872-026-05931-5}
}
EUVIMED